Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports

Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody that binds to and makes all of the VEGF isoforms inactive, and thus prevents angiogenesis, development, and the spread of the tumor. The most reported side effects after administering bevacizumab include bleeding, hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehman, Shafi, Ullah, Hameed, Nagarajan, Jai Sivanandan, Sukaina, Mahnoor, Ghafoor, Bushra, Shaik Masthan, Shameera, Shahrukh, Shazmah, Min Allah, Hassan, Qureshi, Muhammad Hamza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414787/
https://www.ncbi.nlm.nih.gov/pubmed/36043019
http://dx.doi.org/10.7759/cureus.27338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414787/
https://www.ncbi.nlm.nih.gov/pubmed/36043019
http://dx.doi.org/10.7759/cureus.27338

Ejemplares similares